In a report released today, Caroline Palomeque from Maxim Group initiated coverage with a Buy rating on Genprex Inc (NASDAQ: GNPX) and a price target of $5. The company’s shares closed yesterday at $2.20, close to its 52-week low of $2.16.
“We are initiating coverage of Buy rating and $5 price target. The company’s lead therapeutic candidate is Oncoprex, a novel gene-therapy- based approach for treating non-small cell lung cancer (NSCLC), a $15B market.”
According to TipRanks.com, Palomeque is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.7% and a 35.2% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, VistaGen Therapeutics, and Anavex Life Sciences.
The word on The Street in general, suggests a Hold analyst consensus rating for Genprex Inc.
The company has a one-year high of $19.45 and a one-year low of $2.16. Currently, Genprex Inc has an average volume of 76.39K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.